Mice Model

Mice Model

Global Mice Model Market to Reach US$2.6 Billion by 2030

The global market for Mice Model estimated at US$1.9 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection Technology segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$490.0 Million While China is Forecast to Grow at 8.1% CAGR

The Mice Model market in the U.S. is estimated at US$490.0 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Mice Model Market - Key Trends & Drivers Summarized

What Are Mice Models, and Why Are They Crucial in Biomedical Research?
Mice models are laboratory mice used by scientists to study human diseases, genetics, and drug responses. These models are essential for biomedical research because mice share many physiological and genetic similarities with humans, making them excellent subjects for studying a wide range of human conditions, including cancer, heart disease, diabetes, and neurological disorders. The ability to manipulate the mouse genome and create genetically modified mice has significantly enhanced the value of these models in research, allowing for targeted studies on specific genes or disease processes. This capability makes mice models indispensable tools for understanding disease mechanisms, identifying potential therapeutic targets, and evaluating new drugs and treatments.

How Are Genetic Modifications Advancing Mice Model Research?
Genetic modifications in mice models have revolutionized biomedical research, allowing for more precise and targeted studies. Techniques such as CRISPR/Cas9 gene editing have made it possible to create mice with specific genes knocked out or modified, which can mimic human genetic conditions or diseases closely. These advancements have not only accelerated the pace of research but also improved the relevance of mice models to human health. As these techniques become more refined, they enhance the ability to model complex human diseases in mice, leading to more effective drugs, faster development timelines, and ultimately, better patient outcomes.

What Challenges Do Researchers Face With Mice Models?
Despite their extensive use, researchers face challenges with mice models, particularly concerning the accuracy with which these models replicate human diseases. Differences in mouse and human immune systems, metabolism, and biology can lead to discrepancies in how diseases manifest and respond to treatments in mice versus humans. Additionally, the high costs associated with developing, maintaining, and housing genetically engineered mice can be prohibitive, especially in high-throughput studies or in institutions with limited funding. Ethical considerations also play a significant role, as the welfare of animals in research must be meticulously managed to adhere to ethical standards and regulatory guidelines.

What Drives the Growth in the Mice Model Market?
The growth in the mice model market is driven by several factors, including the ongoing need for effective models in the rapidly expanding fields of genetics and personalized medicine. Innovations in genetic engineering and genome editing technologies have broadened the applications of mice models in research, making them more valuable for studying complex genetic interactions and diseases. The rise in chronic diseases globally and the push for more personalized, targeted therapies have also spurred demand for specialized mice models. Furthermore, the increasing investment in pharmaceutical R&D, coupled with growing collaborations between academic institutions and biotechnology companies, supports the continuous development and refinement of mice models. As the biomedical landscape evolves with new scientific advancements and regulatory requirements, the reliance on mice models is expected to remain strong, driving further innovations and expansions in this vital market.

Select Competitors (Total 46 Featured) -
  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Mice Model – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Biomedical Research Advances Drive Demand for Genetically Modified Mice Models
Rising Prevalence of Chronic Diseases Amplifies Need for Effective Mice Models
Technological Innovations in Gene Editing Propel Development of Specialized Mice Models
Pharmaceutical Industry Focus on Personalized Medicine Boosts Use of Mice Models
Advancements in Cancer Research Reliance on Mice Models for Drug Development
Ethical and Regulatory Developments Impact Mice Model Use and Care
Expansion of Contract Research Organizations (CROs) Increases Availability of Mice Models
Educational Institutions Research Needs Support Growth in Mice Model Market
Development of Disease-Resistant Mice Models Opens New Research Avenues
3D Printing and Synthetic Biology Impact Mice Model Development
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Mice Model Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for CRISPR / CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Quarantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Model-In Licensing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: World 16-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 45: World Historic Review for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: World 16-Year Perspective for Immunology & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 48: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 50: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 51: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 53: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 54: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 56: USA Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: USA Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: USA 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 59: USA Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: USA 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 62: USA Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: USA Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: USA 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
CANADA
TABLE 65: Canada Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Canada 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 68: Canada Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Canada 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 71: Canada Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Canada Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Canada 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
JAPAN
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 74: Japan Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Japan 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 77: Japan Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Japan 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 80: Japan Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Japan Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Japan 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
CHINA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 83: China Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: China Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: China 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: China 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 89: China Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: China Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: China 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
EUROPE
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 92: Europe Recent Past, Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Europe 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
FRANCE
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 104: France Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: France Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: France 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 107: France Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: France 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 110: France Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: France Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: France 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
GERMANY
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 113: Germany Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Germany Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: Germany 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 116: Germany Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Germany 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 119: Germany Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Germany Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: Germany 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
ITALY
TABLE 122: Italy Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Italy Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Italy 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 125: Italy Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Italy 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 128: Italy Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Italy Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Italy 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
UNITED KINGDOM
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 131: UK Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: UK Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: UK 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 134: UK Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: UK 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 137: UK Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: UK Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: UK 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
SPAIN
TABLE 140: Spain Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Spain Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Spain 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 143: Spain Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Spain 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 146: Spain Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Spain Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Spain 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
RUSSIA
TABLE 149: Russia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Russia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Russia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 152: Russia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Russia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 155: Russia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Russia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Russia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Rest of Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Rest of Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 168: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Asia-Pacific 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 171: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
AUSTRALIA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 179: Australia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: Australia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: Australia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 182: Australia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: Australia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 185: Australia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: Australia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: Australia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
INDIA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 188: India Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: India Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: India 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 191: India Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: India 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 194: India Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: India Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: India 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 197: South Korea Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: South Korea Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: South Korea 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 200: South Korea Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: South Korea 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 203: South Korea Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: South Korea 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
LATIN AMERICA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 215: Latin America Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 216: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 217: Latin America 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 218: Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 219: Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 220: Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 221: Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 222: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 223: Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 224: Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 225: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 226: Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 227: Argentina Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 228: Argentina Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 229: Argentina 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 230: Argentina Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 231: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 232: Argentina 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 233: Argentina Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 234: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 235: Argentina 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
BRAZIL
TABLE 236: Brazil Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 237: Brazil Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 238: Brazil 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 239: Brazil Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 240: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 241: Brazil 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 242: Brazil Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 243: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 244: Brazil 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
MEXICO
TABLE 245: Mexico Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 246: Mexico Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 247: Mexico 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 248: Mexico Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 249: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 250: Mexico 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 251: Mexico Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 252: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 253: Mexico 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 255: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 256: Rest of Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 258: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 259: Rest of Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 261: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 262: Rest of Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
MIDDLE EAST
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 263: Middle East Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 264: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 265: Middle East 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 266: Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 267: Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 268: Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 269: Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 270: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 271: Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 272: Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 273: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 274: Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
IRAN
TABLE 275: Iran Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 276: Iran Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 277: Iran 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 278: Iran Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 279: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 280: Iran 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 281: Iran Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 282: Iran Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 283: Iran 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
ISRAEL
TABLE 284: Israel Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 285: Israel Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 286: Israel 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 287: Israel Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 288: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 289: Israel 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 290: Israel Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 291: Israel Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 292: Israel 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 294: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 295: Saudi Arabia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 297: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 298: Saudi Arabia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 300: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 301: Saudi Arabia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 302: UAE Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 303: UAE Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 304: UAE 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 305: UAE Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 306: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 307: UAE 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 308: UAE Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 309: UAE Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 310: UAE 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 312: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 313: Rest of Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 315: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 316: Rest of Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 318: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 319: Rest of Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
AFRICA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 320: Africa Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 321: Africa Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 322: Africa 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
TABLE 323: Africa Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 324: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 325: Africa 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
TABLE 326: Africa Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 327: Africa Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 328: Africa 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings